FS069 ultrasound contrast agent: Will begin a Phase III trial in 200 patients in 30 to 45 days

Molecular Biosystems Inc. (MB), San Diego Product: FS069 ultrasound contrast agent Indication: Enhance ability to view the endocardial borders and left ventricle Status: Will begin a Phase III trial ...